CD44 Standard Isoform; Not a Good Marker for Colon Cancer

Rohani, P and Modarresi, P and Noroozinia, F and Abbasi, A (2017) CD44 Standard Isoform; Not a Good Marker for Colon Cancer. Int J Cancer Manag. 2017 September; 10(9):e9166., 10 (9). e9166-e9170.

[thumbnail of 900.pdf]
Preview
Text
900.pdf

Download (3MB) | Preview

Abstract

CD44 isoforms are known to be possible diagnostic and prognostic markers in colorectal cancer (CRC).
Objectives: The present study aims at investigating the expression of CD44 standard(CD44s) isoform in CRC by immunohistochemistry (IHC) as well as exploring its clinicopathological correlations.
Methods: A total of 102 patients, who underwent surgery for primary colorectal adenocarcinoma, were enrolled in this study. IHC
staining for CD44 was performed on pathology samples and defined as: staining < 10% as low/weak, 10% - 50% as moderate, and >
50% as strong/extensive expression level.
Results: The patients’ mean age was 62.8 ± 15.67 years. IHC staining for CD44s demonstrated low expression level in 56%, moderate
in 24%, and extensive in 20% of the participants. The only association was found between CD44 expression level and patients’ age (P
= 0.03) as 25% of tumors in patients younger than 60 years old expressed CD44 expression strongly in contrast to 16.1% of the patients
older than 60 years old. No other association was found between tumor histology, stage, gender, tumor location, lymphovascular
invasion, perineural invasion, lymph node metastasis, or tumor subtype (P > 0.05).
Conclusions: No relation was found between CD44s expression and any tumoral characteristics of CRC. It seems that CD44s are not
helpful in improving the prognostic or diagnostic power in CRC.

Item Type: Article
Uncontrolled Keywords: CD44, Isoform, Colorectal Cancer
Subjects: R Medicine > R Medicine (General)
Depositing User: Unnamed user with email gholipour.s@umsu.ac.ir
Date Deposited: 25 Apr 2018 05:50
Last Modified: 24 Jun 2019 06:46
URI: https://eprints.umsu.ac.ir/id/eprint/4723

Actions (login required)

View Item
View Item